PA5-50932

antibody from Invitrogen Antibodies

Targeting: CMKLR1 RVER1

Provider product page for PA5-50932

Western blot

Immunohistochemistry

Other assay

Antibody data

Antibody Data
Antigen structure
References [2]
Comments [0]
Validations
Other assay [4]

Submit

Product number: PA5-50932 - Provider product page
Provider: Invitrogen Antibodies
Product name: CMKLR1 Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Synthetic peptide
Description: CHEMR23 / CMKLR1 Polyclonal Antibody detects endogenous levels of CHEMR23 / CMKLR1 protein.
Reactivity: Human, Mouse, Rat
Host: Rabbit
Isotype: IgG
Vial size: 100 µL
Concentration: 1 mg/mL
Storage: -20° C, Avoid Freeze/Thaw Cycles

CMKLR1 protein structure - PA5-50932 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Identification of RvE1's receptor on cumulus cells (CCs) and oocytes. (A) Detection of ChemR23 expression on CCs by western blot. THP-1 as a positive control; beta-actin as the internal reference. Three independent biological replicates. (B) The presence of ChemR23 (green) on CCs and oocyte was analyzed by fluorescence microscope. The nuclei of CCs and oocyte were stained with DAPI (blue). The outside silhouette of oocyte was presented by a white ring manually. Three independent biological replicates.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Downregulation of CMKLR1 inhibit VSMCs proliferation and migration. ( A , B ) Percentage of 5-Ethynyl-2'-deoxyuridine (EdU)-incorporated cells following the application of two independent shRNAs targeting CMKLR1 (scramble control, SC; shCMKLR1#2, shCM#2; shCMKLR1#3, shCM#3) to knock down CMKLR1 expression in mice vascular smooth muscle cells (VSMCs). *, p < 0.05; **, p < 0.01. ( C , D ) Percentage of cell migration as determined by wound healing assay. *, p < 0.05; **, p < 0.01. ( E ) Western blots showing CMKLR1, MMP-9 and PCNA expressions in cells treated with PDGF (48 h) for different durations. ( F ) Western blots showing CMKLR1, matrix metalloproteinase-9 (MMP-9) and proliferating cell nuclear antigen (PCNA) expression in cells treated with chemerin-9 (48 h) for different durations. ( G ) Western blots showing CMKLR1, MMP-9 and PCNA expressions with or without CMKLR1 knockdown. ( H ) Western blots showing CMKLR1, MMP-9 and PCNA expressions following the application of plasmids encoding CMKLR1 to overexpress CMKLR1 expression in VSMCs with or without CMKLR1 knockdown. ( I ) Analysis of the percentage EdU-incorporated cells with or without LCN2 depletion. ****, p < 0.0001; **, p < 0.01; ns, no significant difference. ( J ) Percentage of cell migration as determined by wound healing assay. ****, p < 0.0001; **, p < 0.01.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 LCN2 is essential for the inhibition of VSMCs proliferation by CMKLR1 depletion. ( A ) IHC analysis of Lipocalin-2 (LCN2) expression in aorta tissues of mice fed with normal and HFD. Scale bar = 100 mum. Red arrows indicate plaques. ( B ) Chemerin expression score analysis data presented as the means +- SDs. **, p < 0.01. ( C ) Western blots showing LCN2, MMP-9, and beta-catenin expression in cells treated with chemerin-9 (48 h) for different durations. ( D ) Western blot showing LCN2, MMP-9, and beta-catenin expression, with or without CMKLR1 knockdown. ( E ) mRNA expression of LCN2, with or without CMKLR1 depletion, as determined by quantitative real-time PCR. ( F ) Western blots showing CMKLR1 and LCN2 expression following the application of plasmids encoding CMKLR1 to overexpress CMKLR1 expression in VSMCs with or without CMKLR1 depletion. ( G ) Western blots showing CMKLR1, LCN2, PCNA and MMP-9 expression following the application of plasmids encoding LCN2 to overexpress LCN2 expression in VSMCs with or without CMKLR1 depletion. ( H ) Analysis of the percentage EdU-incorporated cells. ****, p < 0.0001; ns, no significant difference. ( I ) Cell migration as determined by wound healing assay. Percentage of cell migration data presented as means +- SDs. ****, p < 0.0001; **, p < 0.01; *, p < 0.05. ( J ) Western blots showing CMKLR1, LCN2, p-AKT, AKT, p-ERK 1/2, ERK 1/2, p-p38, p38, p-PKC and beta-catenin expression following the application of plasmids encoding LCN

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5 Curcumin inhibits CMKLR1 and LCN2 expression. ( A ) IHC analysis of chemerin / CMKLR1 and LCN2 expressions in aorta tissues of HFD ApoE -/- mice with or without curcumin treatment. Scale bar = 100 mum. Red arrows indicate plaques. ( B - D ) Chemerin / CMKLR1 and LCN2 expression score analysis data are presented as means +- SDs. n.s., no significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001. ( E ) Western blots showing CMKLR1, MMP-9, LCN2, beta-catenin and PCNA expressions in cells treated with curcumin (48 h) for different durations. ( F ) mRNA expression of CMKLR1 with or without curcumin treatment (48 h) as determined by quantitative real-time PCR.